XML 26 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
Total
6.50% Convertible Senior Notes Due 2024
August 2019 Bonds
Cumulative Effect, Period of Adoption, Adjustment
 [1]
Preferred stock
Common stock
Common stock
6.50% Convertible Senior Notes Due 2024
Common stock
August 2019 Bonds
Additional paid-in capital
Additional paid-in capital
6.50% Convertible Senior Notes Due 2024
Additional paid-in capital
August 2019 Bonds
Accumulated deficit
Accumulated deficit
Cumulative Effect, Period of Adoption, Adjustment
 [1]
Accumulated other comprehensive income (loss)
Accumulated other comprehensive income (loss)
Cumulative Effect, Period of Adoption, Adjustment
 [1]
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2017         23 90,357,644                    
Beginning balance at Dec. 31, 2017 $ 142,488,809     $ 0 $ 0 $ 90,358     $ 665,775,504     $ (523,356,317) $ 231,366 $ (117,005) $ (231,366) $ 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash (in shares)           5,669,025                    
Issuance of common stock for cash 29,227,776         $ 5,669     29,222,107              
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           1,199,141                    
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 1,809,526         $ 1,199     1,808,327              
Stock-based compensation 10,654,622               10,988,277     (333,655)        
Net loss attributable to common stockholders (96,967,830)                     (96,967,830)        
Unrealized gain (loss) on short-term investments, net of tax (180,496)                         (180,496)    
Foreign currency translation 0                              
Ending balance (in shares) at Dec. 31, 2018         23 97,225,810                    
Ending balance at Dec. 31, 2018 87,032,407       $ 0 $ 97,226     707,794,215     (620,426,436)   (528,867)   96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash (in shares)           3,340,678                    
Issuance of common stock for cash 9,089,009         $ 3,340     9,085,669              
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           794,546                    
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (780,405)         $ 795     (781,200)              
Equity component of issuance of convertible notes 15,752,698               15,752,698              
Stock-based compensation 10,901,320               10,795,403             105,917
Acquisition of non-controlling interest in Geneos, net 2,960,131                             2,960,131
Net loss attributable to common stockholders (120,551,777)                     (119,359,219)       (1,192,558)
Unrealized gain (loss) on short-term investments, net of tax 1,001,475                         1,001,475    
Foreign currency translation 0                              
Ending balance (in shares) at Dec. 31, 2019         23 101,361,034                    
Ending balance at Dec. 31, 2019 5,404,858       $ 0 $ 101,361     742,646,785     (739,785,655)   472,608   1,969,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash (in shares)           66,064,886                    
Issuance of common stock for cash 454,486,400         $ 66,065     454,420,335              
Conversion of preferred stock/senior notes to common stock (in shares)         (14) 5,147 11,535,660 4,962,364                
Conversion of preferred stock/senior notes to common stock 0 $ 43,694,386 $ 102,671,310     $ 5 $ 11,536 $ 4,961 (5) $ 43,682,850 $ 102,666,349          
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           2,922,402                    
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 8,241,624         $ 2,923     8,238,701              
Stock-based compensation 15,647,523               15,655,585             (8,062)
Acquisition of non-controlling interest in Geneos, net 2,379,969                             2,379,969
Deconsolidation of Geneos (3,181,640)                             (3,181,640)
Net loss attributable to common stockholders (167,474,914)                     (166,411,157)       (1,063,757)
Dissolution of majority-owned subsidiary VGX Animal Health, Inc. 0               96,269             (96,269)
Unrealized gain (loss) on short-term investments, net of tax (755,963)                         (755,963)    
Foreign currency translation 27,205                         27,205    
Ending balance (in shares) at Dec. 31, 2020         9 186,851,493                    
Ending balance at Dec. 31, 2020 $ 461,140,758       $ 0 $ 186,851     $ 1,367,406,869     $ (906,196,812)   $ (256,150)   $ 0
[1] Upon adoption of ASU 2016-01 on January 1, 2018, the Company began to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and began to recognize the changes in fair value in its consolidated statements of operations, instead of recognizing unrealized gains and losses through accumulated other comprehensive income (loss), as done under the previous guidance. The Company recorded a $231,000 cumulative effect adjustment to reclassify the cumulative unrealized gain, net of tax effect, from its investment in an affiliated entity, PLS, from accumulated other comprehensive loss to accumulated deficit.